$4450
$3560
The fluorine-18 market size is projected to reach US$ 2.53 billion by 2031 from US$ 1.85 billion in 2024. The market is expected to register a CAGR of 4.7% during 2025–2031.
Fluorine-18 Market Analysis
The market's growth is driven by the rising prevalence of cancers, increasing pet imaging, technological advancements in PET scanners and imaging systems, and regulatory approvals and development of novel fluorine-18 tracers. Integration of artificial intelligence in fluorine-18 imaging analysis and development of novel fluorine-18 tracers contributes to market development. Expansion of theranostic applications with fluorine-18 tracers and growth in neurological applications for fluorine-18 tracers is expected to create ample opportunities for the fluorine-18 market growth.
Fluorine-18 Market Overview
The fluorine-18 market is driven by the increasing global incidence of cancer as well as advancement in the field of nuclear medicine. Besides the dominant role of Fluorodeoxyglucose (FDG), which accounts for more than 80% of the PET-CT scan market, the usage of PET in cardiology and the central nervous system is also increasing rapidly. Apart from that, GE HealthCare's introduction of Flyrcado (flurpiridaz F 18) in 2025 for myocardial perfusion imaging is expected to be a milestone in cardiovascular assessments, as the precision of the technique will be improved considerably. Hospitals are the leading end-users of the sector, which creates the highest volume of demand. The characteristic of the isotope, such as its limited life (110 minutes), has induced new installations of cyclotrons at the site. Due to the availability of cutting-edge technology in the region, North America is still the most significant geographical area for the market. However, Asia Pacific has become a high-potential market owing to the influx of healthcare investments and is the most likely area for market growth.
Customize Research To Suit Your Requirement
We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.
Fluorine-18 Market: Strategic Insights
Market Size Value in US$ 1.72 billion in 2022 Market Size Value by US$ 2.41 billion by 2030 Growth rate CAGR of 4.3% from 2022 to 2030 Forecast Period 2022-2030 Base Year 2022
Mrinal
Have a question?
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
Fluorine-18 Market Drivers and Opportunities
Customize Research To Suit Your Requirement
We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.
Fluorine-18 Market: Strategic Insights
| Market Size Value in | US$ 1.72 billion in 2022 |
| Market Size Value by | US$ 2.41 billion by 2030 |
| Growth rate | CAGR of 4.3% from 2022 to 2030 |
| Forecast Period | 2022-2030 |
| Base Year | 2022 |
Mrinal
Have a question?
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
Market Drivers:
Rising Prevalence of Cancers Increasing PET Imaging:
One of the main reasons for the rise in demand for Fluorine-18 radiotracers is the worldwide increase in cancer incidence, with a significant proportion of cancers being those tumors whose metabolic profiling by Fluorine-18-based positron emission tomography (PET) scans is possible.Technological Advancements in PET Scanners and Imaging Systems:
The advances in positron emission tomography (PET) hardware and combined modalities have significantly increased the use of clinically relevant Fluorine-18 radiotracers, allowing the figures to surpass their previous limits as diagnostic tools.Regulatory Approvals and Development of Novel Fluorine-18 Tracers:
One of the main factors which have boosted the market for Fluorine-18-labeled innovative tracers is the increasing number of regulatory approvals. Besides broadening the therapeutic windows, these tracers have been able to increase the specificity of the disease over a wide range of pathologies, which has made their clinical integration and production requirements to progress rapidly.
Market Opportunities:
Expansion of Theranostic Applications with Fluorine-18 Tracers:
Combining Fluorine-18 PET with theranostic systems can open the way for a major change in the Fluorine-18 market, that is, diagnostic accuracy as well as therapy monitoring can be made possible.Growth in Neurological Applications for Fluorine-18 Tracers :
A major source of opportunity for the Fluorine-18 market is the increasing usage of the neuroimaging field, which comes from the escalating occurrence of nervous system diseases, amongst which Alzheimer’s disease and other dementias take the leading position.Advancements in Automated Synthesis and Production Technologies:
One of the major changes that led to a significant step in simplifying the production of Fluorine-18 radiotracers is the invention of automated synthesis modules. These innovations provide a great chance for improving production efficacy, saving money, and opening new markets.
Fluorine-18 Market Report Segmentation Analysis
The fluorine-18 market is divided into different segments to give a clearer view of how it works, its growth potential, and the latest trends. Below is the standard segmentation approach used in most industry reports:
By Product Type:
FDG:
FDG (fluorodeoxyglucose) is the most important radiotracer for positron emission tomography (PET) imaging, basically due to its function to make visible the glucose metabolism in pathological tissues. The half-life of FDG is about 110 minutes, which makes it necessary to be produced by a cyclotron on-site, allowing a quick delivery to the imaging centers for use on the same day.NaF:
Sodium Fluoride (NaF) is recognized as the most effective agent for localizing bone changes, particularly in metastatic bone disease, which is why it is the primary diagnostic tool in cancer diseases. Because the product has high bone affinity, it allows for the acquisition of accurate images of skeletal structures, thereby providing better sensitivity compared to conventional bone scintigraphy agents.Others:
The Others encompasses several non-FDG radiotracers such as FLT (fluorothymidine), FMISO (fluoromisonidazole), and FET (fluoroethyltyrosine) that are leading to the development of new diagnostic areas that utilize PET imaging technology. The tracers are the main source for the rare indications of oncology, neurology, and hypoxia imaging fields.
By Application:
- Oncology
- Cardiology
- Neurology
- Others
By End-User Industry:
- Hospitals
- Diagnostic and Imaging Centers
- Others
Each end user in the Fluorine-18 market has distinct handling, safety, and regulatory needs, shaping equipment selection and operational protocols.
By Geography:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
The fluorine-18 market in Asia Pacific is expected to witness the fastest growth. The surging demand for positron emission tomography (PET) imaging, driven by rising cancer incidences and expanding healthcare infrastructure, is likely to drive the market.
Fluorine-18 Market Report ScopeFluorine-18 Market Share Analysis by Geography
Asia Pacific is expected to grow the fastest in the next few years. Emerging markets in Latin America, the Middle East, and Africa also have many untapped opportunities for fluorine-18 providers to expand.
The fluorine-18 market grows differently in each region owing to the increasing prevalence of oncology and other conditions, technological advancements in PET scanners and imaging systems, along with regulatory approvals and the development of F-18 tracers. Below is a summary of market share and trends by region:
1. North America
Market Share:
Holds a significant portion of the global marketKey Drivers:
- The rising demand for PET imaging in oncology, the increased prevalence of cancer, advancements in radiopharmaceuticals, and growing investments in nuclear medicine infrastructure
Trends:
Advancements in radiopharmaceutical production
2. Europe
Market Share:
Substantial share due to early adoption of Fluorine-18 for PET ImagingKey Drivers:
- Increasing cancer incidence, growing preference for PET imaging, supportive government healthcare initiatives, and expanding use of radiopharmaceuticals in personalized and precision medicine.
Trends:
Increasing integration of Fluorine-18 in personalized medicine
3. Asia Pacific
Market Share:
Fastest-growing region with rising market share every yearKey Drivers:
- Rising healthcare expenditure, increasing awareness of early cancer diagnosis, expanding PET imaging facilities, and growing investment in nuclear medicine and radiopharmaceutical research.
Trends:
Growing partnerships between hospitals and radiopharmaceutical companies
4. South and Central America
Market Share:
Growing market with steady progressKey Drivers:
- Increasing cancer cases, improving healthcare infrastructure, rising awareness of nuclear medicine, and growing adoption of PET imaging technologies in urban centers.
Trends:
Increasing healthcare modernization
5. Middle East and Africa
Market Share:
Although small, but growing quicklyKey Drivers:
- Expanding diagnostic imaging capabilities, rising government investments in healthcare, growing prevalence of chronic diseases, and increased access to radiopharmaceuticals.
Trends:
Growing government initiatives for cancer diagnosis
Fluorine-18 Market Players Density: Understanding Its Impact on Business Dynamics
High Market Density and Competition
Competition is strong due to the presence of established players, such as Lantheus Holdings, Advanced Accelerator Applications, Curium Pharma, and Jubilant Pharma Limited, which are also adding to the competitive landscape across different regions.
This high level of competition urges companies to stand out by offering:
- Advanced security features
- Value-added services such as Analytics & predictive maintenance, real?time operational analytics, and installation
- Competitive pricing models
- Strong customer support and easy integration
Opportunities and Strategic Moves
- Development of new F-18 labeled radiopharmaceuticals for diagnosis and targeted therapy in oncology, neurology, and cardiology is accelerating market growth. The expansion of PET imaging capabilities and the adoption of precision medicine are spurring demand for F-18 products, particularly as they enable early cancer detection and improved treatment monitoring.
- Leading industry players are establishing exclusive partnerships for technology transfer and regulatory support, notably in regions with high disease prevalence, such as China.
- Recent FDA and European approvals for novel F-18 tracers (e.g., flotufolastat, Pylclari) support enhanced imaging of prostate and cardiovascular conditions. Companies are investing in research to improve cyclotron yields, lower costs, and decentralize isotope production, aiding wider market access
Other companies analysed during the course of research:
- GE Healthcare
- Siemens Healthineers
- Cardinal Health
- Lantheus Medical Imaging
- Curium Pharma
- IBA Radiopharma Solutions
- Eckert & Ziegler Radiopharma
- Advanced Accelerator Applications
- Bracco Imaging
- Jubilant Radiopharma
- Positron Corporation
- Nordion (Canada) Inc.
- Blue Earth Diagnostics
- PETNET Solutions Inc.
- SOFIE Biosciences
Fluorine-18 Market News and Recent Developments
Lantheus and GE HealthCare Announced Exclusive Licensing Agreement for Prostate Cancer Imaging Agent PYLARIFY in Japan
Lantheus Holdings, Inc. and GE HealthCare announced an exclusive licensing agreement for GE HealthCare to develop, manufacture, and commercialize Lantheus’ piflufolastat F18 (PYLARIFY in the US market) in Japan for prostate cancer diagnostics and companion diagnostic use.GE HealthCare received FDA approval of Flyrcado (flurpiridaz F 18) injection PET radiotracer for enhanced diagnosis of coronary artery disease
GE HealthCare’s FDA-approved flurpiridaz F 18 PET radiotracer, Flyrcado, delivers higher diagnostic efficacy in patients with known or suspected coronary artery disease (CAD), compared to SPECT MPI, the predominant procedure used in nuclear cardiology.Lantheus Receives U.S. FDA Approval of PYLARIFY (piflufolastat F 18) Injection, the First and Only Commercially Available PSMA PET Imaging Agent for Prostate Cancer
Lantheus Holdings received the US Food and Drug Administration (FDA) approval for PYLARIFY, an F 18-labeled prostate-specific membrane antigen (PSMA) targeted positron emission tomography (PET) imaging agent to identify suspected metastasis or recurrence of prostate cancer. PYLARIFY is the first and only commercially available approved PSMA PET imaging agent for prostate cancer.
Fluorine-18 Market Report Coverage and Deliverables
The "Fluorine-18 Market Size and Forecast (2021–2031)" report provides a detailed analysis of the market covering below areas:
- Fluorine-18 Market size and forecast at global, regional, and country levels for all the key market segments covered under the scope
- Fluorine-18 Market trends, as well as market dynamics such as drivers, restraints, and key opportunities
- Detailed PEST and SWOT analysis
- Fluorine-18 Market analysis covering key market trends, global and regional framework, major players, regulations, and recent market developments
- Industry landscape and competition analysis covering market concentration, heat map analysis, prominent players, and recent developments for the Fluorine-18 Market
- Detailed company profiles
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
Product Type, Application, End User, and Geography
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
The fluorine 18 market is estimated to reach a value of US$ 2.53 billion by 2031.
Lantheus Medical Imaging Inc; Siemens Healthineers AG; GE HealthCare Technologies Inc; Curium Pharma; Blue Earth Diagnostics Limited; Eli Lilly and Co; IBA Radiopharma Solutions are among the key players operating in the fluorine 18 market.
North America dominated the market in 2024.
Rising prevalence of cancers, increasing pet imaging, technological advancements in PET scanners and imaging systems, and regulatory approvals and development of novel fluorine-18 tracers are among the factors propelling the market growth.
The fluorine 18 market is estimated to register a CAGR of 4.7% during the forecast period.
The List of Companies - Fluorine-18 Market
- Lantheus Medical Imaging Inc
- Siemens Healthineers AG
- GE HealthCare Technologies Inc
- Curium Pharma
- Blue Earth Diagnostics Limited
- Eli Lilly and Co
- IBA Radiopharma Solutions
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Trends and growth analysis reports related to Fluorine-18 Market
Oct 2025
Urokinase API and Finished Dosage Forms Market
Size and Forecast (2021 - 2031), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Product Type (Active Pharmaceutical Ingredient and Finished Dosage Forms), Manufacturing Process (Urine-derived, Cell Culture-based, and Recombinant Technology), Indication (Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), Catheter Occlusion, Myocardial Infarction (Heart Attack), Peripheral Arterial Occlusive Diseases, and Others), Distribution Channel (Hospital Pharmacies, Retail and Drug Stores, Direct Sales (API and FDF), and Online Pharmacies), and Geography (North America, Europe, Asia Pacific, Middle East and Africa, and South and Central America)
Oct 2025
Aesthetic Fillers and Exosomes Market
Size and Forecast (2021 - 2031), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Product Type [Dermal Fillers (Calcium Hydroxylapatite, Hyaluronic Acid, Collagen, Poly-L-Lactic Acid, Polymethylmethacrylate (PMMA), Fat Fillers, and Others) and Exosome-Based Aesthetic Products (Human-derived, Animal-derived, and Plant-derived)], Route of Administration [Injectable, Topical (Serum, Cream, Mask, and Others)], Application (Skin Rejuvenation, Wrinkle Reduction and Fine Line Correction, Facial Contouring, Lip Augmentation, Scar and Pigmentation, Post-procedure Recovery, Hair Restoration, and Others), End User (Hospitals, Dermatology Clinics, Medical Spas, and Others), and Geography (North America, Europe, and Middle East)
Oct 2025
Veterinary Diagnostics Products Market
Size and Forecast (2021 - 2031), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Product (Kits and Reagents [ELISA Test Kits, Antibodies Test Kits, Polymerase Chain Reaction (PCR) Test Kits, Hematology Test Kits, Biochemistry Test Kits, Immunoassay Reagents, and Others]and Analyzers [Biochemistry Analyzers, Hematology Analyzers, Immunoassay Analyzers, PCR Analyzers, and Others]), Animal Type (Companion Animal [Dogs, Cats, Horses, and Others] and Livestock Animal [Cattles, Pigs, Poultry, and Others]), Application (Infectious Diseases [Rabies, Avian Influenza, Leishmania, Methicillin-Resistant Staphylococcus Aureus (MRSA) Infection, and Others] and Non-Infectious Diseases [Pneumonia, Gastritis, Bronchitis, and Others]), End User (Public Healthcare Facilities and Private Healthcare Facilities), and Geography (North America, Europe, Asia Pacific, Middle East and Africa, and South and Central America)
Oct 2025
High Potent Pharmaceuticals Product Market
Size and Forecast (2021 - 2031), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Product Type [APIs (Synthetic High Potency Active Pharmaceutical Ingredients and Biotech High Potency Active Pharmaceutical Ingredients) and Finished Dosage Forms (Tablets, Capsules, Injectables, and Others)], Drug Type (Innovative Drugs and Generic Drugs), Indication (Oncology, Hormonal Disorders, Autoimmune or Immunology, Infectious Diseases, CNS Disorders, Cardiovascular Diseases, and Others), Manufacturing Type (In-House Manufacturing and Outsourced (Contract Manufacturing)), Distribution Channel (Hospital Pharmacies, Retail and Drug Stores, Online Pharmacies, and Others)
Oct 2025
Delay Condoms Market
Size and Forecast (2021 - 2031), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Product Type (Condoms and Dental Dams), Category (Flavored and Plain), Material (Latex and Non-Latex), Distribution Channel (Supermarkets and Hypermarkets, Pharmacies and Drug Stores, Online Retails and Others), and Geography
Oct 2025
Wheelchair and Mobility Aids Market
Size and Forecast (2021 - 2031), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Product (Wheelchairs (Manual, Powered, Power Assisted, and Accessories), Mobility Scooters, Walking Aids, and Others), Application (Neurologically Impaired, Handicap Patients, and Other Applications), End User (Homecare, Hospitals and Clinics, Rehabilitation Centers, and Others), and Distribution Channel (Online and Offline)
Oct 2025
Cystoscopy and Ureteroscopy Market
Size and Forecast (2021 - 2031), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Product Type [Cystoscope (Rigid and Flexible), and Ureteroscope (Flexible and Semi-Flexible)], Procedure (Stone Management, Bladder Cancer, Benign Prostatic Hyperplasia, and Others), Technology (Fiberoptic and Video), Usage Type (Reusable and Single Use), End User (Hospitals, Ambulatory Surgical Centers and Specialty Clinics), and Geography (North America, Europe, Asia Pacific, Middle East and Africa, South and Central America)
Oct 2025
Cancer Drugs Market
Size and Forecast (2021 - 2031), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Therapy Type (Chemotherapy, Targeted Therapy, Immunotherapy, Hormone Therapy, and Other Therapy Types), By Indications (Blood Cancer, Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Stomach Cancer, Cervical Cancer, Liver and Intrahepatic Bile Ducts Cancer, Thyroid Cancer, and Other Indications), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Stores), and Geography